Abstract: A plant is activated and the activity is promoted by using a product of Trichoderma harzianum SK-5-5 strain. The activation of a plant and the promotion of the activity can be achieved by culturing Trichoderma harzianum SK-5-5 strain in a solid medium and extracting its product, or by applying the conidiospores of the above strain.

Abstract: The present invention is intended to efficiently produce a large amount of chlamydospores of Trichoderma harzianum SK-5-5 mycelia. This objective is achieved by chlamydospores characterized by having been obtained by inoculating a culture medium containing glucose, yeast extract and polypepton with Trichoderma harzianum SK-5-5 mycelia and culturing the same to thereby obtain chlamydospores containing conidiospores.

Abstract: A 5-isoquinolinesulfonyl derivative of Formula (I): ##STR1## wherein l is zero or one;m and n each is an integer of one to nine;m+n is an integer of at least one;R.sub.1 is a hydrogen atom, a C.sub.1-10 alkyl group, a C.sub.5-6 cycloalkyl group or an aryl group; orR.sub.2 and R.sub.3 each is a hydrogen atom, a C.sub.1-10 alkyl group, a C.sub.5-6 cycloalkyl group, an aryl group or an aralkyl group;R.sub.2 and R.sub.3 are C.sub.1-6 alkylene groups and linked directly or through an oxygen atom to form a 5- to 7-membered heterocyclic ring with the adjacent nitrogen atom; or the ##STR2## wherein R.sub.4 and R.sub.5 each is a hydrogen atom, a C.sub.1-10 alkyl group, an aryl group or an aralkyl group and R.sub.6 is a hydrogen atom, a C.sub.1-10 alkyl group, an aryl group, an aralkyl group, a benzoyl group, a cinnamyl group, a cinnamoyl group, a furoyl group or a ##STR3## wherein R.sub.7 is a C.sub.1-8 alkyl group; and the pharmaceutically acceptable salt thereof; and a process for the preparation thereof.

Abstract: A 5-isoquinolinesulfonyl derivative of Formula (I): ##STR1## wherein l is zero or one;m and n each is an integer of one to nine;m+n is an integer of at least oneR.sub.1 is a hydrogen atom, a C.sub.1-10 alkyl group, a C.sub.5-6 cycloalkyl group or an aryl group; orR.sub.2 and R.sub.3 each is a hydrogen atom, a C.sub.1-10 alkyl group, a C.sub.5-6 cycloalkyl group, an aryl group or an aralkyl group;R.sub.2 and R.sub.3 are C.sub.1-6 alkylene groups and linked directly or through an oxygen atom to form a 5- to 7-membered heterocyclic ring with the adjacent nitrogen atom; orthe ##STR2## group is a ##STR3## group wherein R.sub.4 and R.sub.5 each is a hydrogen atom, a C.sub.1-10 alkyl group, an aryl group or an aralkyl group and R.sub.6 is a hydrogen atom, a C.sub.1-10 alkyl group, an aryl group, an aralkyl group, a benzoyl group, a cinnamyl group, a cinnamoyl group, a furoyl group or a ##STR4## group wherein R.sub.7 is a C.sub.

Abstract: A 6-quinazolinesulfonyl derivative of Formula (I): ##STR1## wherein R.sub.1 is a hydrogen atom or a C.sub.1-12 alkyl group:R.sub.2 is a hydrogen atom, a C.sub.1-12 alkyl group, a C.sub.4-10 cycloalkyl group, an aryl group or an aralkyl group; andR.sub.1 and R.sub.2 may be linked directly or through an oxygen atom to form a 5- to 7-membered heterocyclic ring together with the adjacent nitrogen atom; andR.sub.3 is a ##STR2## group wherein R.sub.4 is a C.sub.1-8 alkyl group; a --HN(CH.sub.2).sub.n NH.sub.2 group wherein n is an integer of 2 to 10; or a ##STR3## group; and the pharmaceutically acceptable salt thereof; and a process for the preparation thereof. The compounds of this invention have a relaxatory action for vascular smooth muscle and are useful as a vasodilator and a hypotensor.

Abstract: A 5-isoquinolinesulfonyl derivative of Formula (I): ##STR1## wherein l is zero or one;m and n each is an integer of one to nine;m+n is an integer of at least one;R.sub.1 is a hydrogen atom, a C.sub.1-10 alkyl group, a C.sub.5-6 cycloalkyl group or an aryl group; orR.sub.2 and R.sub.3 each is a hydrogen atom, a C.sub.1-10 alkyl group, a C.sub.5-6 cycloalkyl group, an aryl group or an aralkyl group;R.sub.2 and R.sub.3 are C.sub.1-6 alkylene groups and linked directly or through an oxygen atom to form a 5- to 7-membered heterocyclic ring with the adjacent nitrogen atom; orthe ##STR2## group is a ##STR3## group wherein R.sub.4 and R.sub.5 each is a hydrogen atom, a C.sub.1-10 alkyl group, an aryl group or an aralkyl group and R.sub.6 is a hydrogen atom, a C.sub.1-10 alkyl group, and aryl group, an aralkyl group, a benzoyl group, a cinnamyl group, a cinnamoyl group, a furoyl group or a ##STR4## group wherein R.sub.7 is a C.sub.

Abstract: Novel cyclic adenosine monophosphate derivatives represented by the following general formula: ##STR1## wherein A stands for --S-- or --NH-- and n is an integer of from 2 to 12, ARE SUPERIOR TO KNOWN CYCLIC ADENOSIENE DERIVATIVES IN BIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES, ESPECIALLY PDE-inhibiting activity and membrane permeability. Accordingly, these derivatives are very effective for remedying and controlling diseases caused by disorder of the intracellular cyclic adenosine monophosphate level, such as asthma and scabies. These derivaives can readily be synthesized by reacting an 8-halogeno cyclic adenosine monophosphate of the following general formula ##STR2## wherein X is a halogen atom such as bromine, with an alkali metal salt of a linear alkylmercaptan having 3 to 13 carbon atoms in the alkyl group or a linear alkylamine having 3 to 13 carbon atoms in the alkyl group.